Click to Skip Ad
Closing in...

Doctors found a flu drug that might also be a coronavirus cure

Published Nov 3rd, 2020 9:54AM EST
Coronavirus Treatment
Image: karn/Adobe

If you buy through a BGR link, we may earn an affiliate commission, helping support our expert product labs.

  • Researchers have discovered another potential drug that can help cure COVID-19 by preventing severe coronavirus complications.
  • Aprotinin is an antiviral that comes in the form of an aerosol approved in Russia for flu treatment.
  • According to a new study, the drug can inhibit the coronavirus’s ability to infect cells and prevent it from replicating.

The number of daily COVID-19 cases is breaking new records and thousands of people continue to die each day. But the good news is that the coronavirus fatality curve isn’t quite as severe as the surge in cases. Physicians are saving more people than they could in the early months of the pandemic after developing different treatment protocols that include some effective drugs. Remdesivir and dexamethasone are two of the most well-known COVID-19 therapies, although neither drug can save lives. Remdesivir can hasten recovery in some patients, while dexamethasone can reduce the potentially deadly immune response in severe cases. Blood thinners can reduce the clotting complication that impacts nearly every organ, and blood plasma transfusions can save some lives in certain conditions. But none of those drugs are miracle cures.

There’s still no perfect COVID-19 cure that can significantly cut the risk of transmission — and there are no over-the-counter drugs that would allow patients to treat the illness at home. Doctors are trying several novel therapies in tests, and now a team of scientists from Germany and the UK think they’ve found another drug that can effectively block the replication of SARS-Cov-2 inside the body.

After it gains access to the body, the coronavirus infects cells. The pathogen hooks up to the ACE2 receptor to penetrate the cell membrane. Once inside the cell, it takes over and creates thousands of copies of itself. The host cell is killed in the process, and the new SARS-CoV-2 replicas attack other cells. As that happens, the immune system takes measures to kill the pathogen and get rid of infected tissue.

As the viral load increases inside the body, patients can start experiencing symptoms, including severe ones. These people are also contagious to others. The immune system can mount a defense of varying strength. Some people clear the virus faster, and their condition ameliorates as symptoms subside. Others worsen in a matter of days and risk death.

A team of German and British researchers conducted experiments with aprotinin, a protease inhibitor that can block the virus from entering cells. The antiviral activity of the drug would help reduce the SARS-CoV-2 viral load and improve a patient’s COVID-19 prognosis. The scientists say that the drug may work best if given early after a COVID-19 infection. Aprotinin “may be if limited in late-stage COVID-19 disease.” At that point, it’s the exacerbation of the immune response that needs to be stopped rather than viral replication.

“The main potential of antiviral drugs may lie in the early treatment of COVID-19 patients to suppress virus replication and, through this, to prevent COVID-19 progression into a severe, life-threatening disease,” the researchers write. “Local aprotinin therapy of the airways and the lungs using an aerosol, which is clinically approved in Russia and has been reported to be very well tolerated in influenza patients, may have particular potential as such an antiviral treatment for early-stage COVID-19 disease. Notably, aprotinin may additionally prevent the very early stages of lung injury by inhibition of matrix metalloproteinases and, in turn, of the cytokine storm that eventually results in severe, systemic COVID-19 disease.”

The researchers concluded that aprotinin aerosol “may be a particularly promising strategy to suppress virus replication and lung injury early and to prevent COVID-19 progression into a severe, systemic disease.” But the drug might need additional clinical trials that prove its efficacy for COVID-19 compared to standard care before it can be widely used to treat coronavirus infections.

The full study is available in Cells.

Chris Smith Senior Writer

Chris Smith has been covering consumer electronics ever since the iPhone revolutionized the industry in 2008. When he’s not writing about the most recent tech news for BGR, he brings his entertainment expertise to Marvel’s Cinematic Universe and other blockbuster franchises.

Outside of work, you’ll catch him streaming almost every new movie and TV show release as soon as it's available.

More Science